ArticleOphthalmology science

Bispecific VEGF-A and Angiopoietin-2 Antagonist RO-101 Preclinical Efficacy in Model of Neovascular Eye Disease.

Li Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.